LUNG ALERT..........: A paradox of TB immunity

Dheda, K.
November 2004
Thorax;Nov2004, Vol. 59 Issue 11, p980
Academic Journal
The article focuses on a study which highlights natural infection in tuberculosis does not confer protective immunity yet only 10% of those that are infected progress to active disease. Indeed, recent human molecular epidemiological studies show that previous infection does not protect against re-infection progressing to active disease and, moreover, at the site of human disease there are high IFN-γ levels. The study raises the question of whether the strategy to identify vaccine candidates by using the IFN-γ response as a surrogate marker of protective immunity is a valid one.


Related Articles

  • Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. Smith, Steven G.; Lalor, Maeve K.; Gorak-Stolinska, Patricia; Blitz, Rose; Beveridge, Natalie E. R.; Worth, Andrew; McShane, Helen; Dockrell, Hazel M. // BMC Immunology;2010, Vol. 11, p35 

    Background: The vaccine efficacy reported following Mycobacterium bovis Bacillus Calmette Guerin (BCG) administration to UK adolescents is 77% and defining the cellular immune response in this group can inform us as to the nature of effective immunity against tuberculosis. The aim of this study...

  • Advances in TB vaccinology. Hill, Uta G.; Sander, Clare R. // Current Respiratory Medicine Reviews;Jun2013, Vol. 9 Issue 3, p172 

    Development of a vaccine with enhanced efficacy compared to that of the Bacillus Calmette Guerin (BCG) vaccine is essential to reduce the global TB burden. This is challenging since an effective vaccine will need to induce protection that surpasses that induced by natural infection with M....

  • Concordant or discordant results by the tuberculin skin test and the quantiFERON-TB test in children reflect immune biomarker profiles. Dhanasekaran, S; Jenum, S; Stavrum, R; Ritz, C; Kenneth, J; Vaz, M; Doherty, T M; Grewal, H M S // Genes & Immunity;Jul/Aug2014, Vol. 15 Issue 5, p265 

    The tuberculin skin test (TST) and QuantiFERON-TB-Gold-In-tube (QFTGIT) are adjunctive tests used in the diagnosis of pediatric tuberculosis (TB). Neither test can rule out TB; however, a positive test usually triggers preventive treatment in TB contacts aged <5 years. TST and QFTGIT can give...

  • IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. Kabeer, Basirudeen Syed Ahamed; Raja, Alamelu; Raman, Balambal; Thangaraj, Satheesh; Leportier, Marc; Ippolito, Giuseppe; Girardi, Enrico; Lagrange, Philippe Henri; Goletti, Delia // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p135 

    Background: There is an urgent need of prognosis markers for tuberculosis (TB) to improve treatment strategies. The results of several studies show that the Interferon (IFN)-g-specific response to the TB antigens of the QuantiFERON TB Gold (QFT-IT antigens) decreases after successful TB therapy....

  • Broad Adaptive Immune Responses to M. tuberculosis Antigens Precede TST Conversion in Tuberculosis Exposed Household Contacts in a TB-Endemic Setting. Buchwald, Ulrike K.; Adetifa, Ifedayo M. O.; Bottomley, Christian; Owiafe, Patrick K.; Donkor, Simon; Bojang, Adama L.; Sutherland, Jayne S. // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Background: The identification of Mycobacterium-tuberculosis (Mtb) infected individuals remains a challenge due to an insufficient understanding of immune responses detected with the current diagnostic tests for latent tuberculosis i.e. the tuberculin skin test (TST) or IFN–γ release...

  • Development of BCG Scar and Subsequent Morbidity and Mortality in Rural Guinea-Bissau. Storgaard, Line; Rodrigues, Amabelia; Martins, Cesario; Nielsen, Bibi Uhre; Ravn, Henrik; Benn, Christine Stabell; Aaby, Peter; Fisker, Ane Bærent // Clinical Infectious Diseases;9/15/2015, Vol. 61 Issue 6, p950 

    Background: Previous studies have found that BCG vaccination has nonspecific beneficial effects on child survival, especially among children who developed a BCG scar. These studies have mostly been done in settings with a high scar frequency. In rural Guinea-Bissau, many children do not develop...

  • Immune Correlates of HIV Control. Prado, J. G.; Carrillo, J.; Blanco-Heredia, J.; Brander, C. // Current Medicinal Chemistry;Sep2011, Vol. 18 Issue 26, p3963 

    The development of an effective HIV vaccine is still hampered by the lack of clearly defined immune correlates of HIV control. Although a number of immune markers have been associated over last years with relative viral control and slower HIV disease progression, these associations are...

  • Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative Vaccines. Lewis, David J. M.; Lythgoe, Mark P. // Journal of Immunology Research;8/25/2015, Vol. 2015, p1 

    Advances in "omics" technology (transcriptomics, proteomics, metabolomics, genomics/epigenomics, etc.) allied with statistical and bioinformatics tools are providing insights into basic mechanisms of vaccine and adjuvant efficacy or inflammation/reactogenicity. Predictive biomarkers of...

  • The Impact of Transcriptomics on the Fight against Tuberculosis: Focus on Biomarkers, BCG Vaccination, and Immunotherapy. Zárate-Bladés, Carlos Rodrigo; Silva, Celio Lopes; Passos, Geraldo A. // Clinical & Developmental Immunology;2011, p1 

    In 1882 Robert Koch identified Mycobacterium tuberculosis as the causative agent of tuberculosis (TB), a disease as ancient as humanity. Although there has been more than 125 years of scientific effort aimed at understanding the disease, serious problems in TB persist that contribute to the...


Read the Article


Sign out of this library

Other Topics